Clinical trial · Interventional
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
Phase I, Open-Label Study To Assess the Safety, Tolerability and Pharmacokinetics of Daily Oral Doses of Cediranib (RECENTIN™;AZD2171) (20, 30 or 45mg) When Co-Administered With Daily Oral Doses of AZD0530 (125mg or 175mg) in Patients With Advanced Solid Tumours
NCT00475956CI-TRIAL-00003369completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to determine if the maximum tolerated doses of AZD2171, in combination with AZD0530, in treating patients with advanced solid tumours are safe, tolerable and efficacious.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AZD0530 | Drug | — | UNRESOLVED |
| AZD2171 | Drug | Cediranib | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- description
- AZD2171 Monotherapy
- interventionNames
- Drug: AZD2171
- type
- EXPERIMENTAL
- label
- 2
- description
- AZD2171 + AZD0530
- interventionNames
- Drug: AZD2171
- Drug: AZD0530
Primary outcomes (1)
- measure
- Determine the safety and tolerability of ascending daily oral doses of AZD2171 when co-administered with AZD0530 to patients with advanced solid tumours by assessment of AEs, vital signs, HRCT Scans, clin chem, haematology, urinalysis, ECG and phys exam
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written consent * Cancer diagnosis \& stage * Patients for whom no standard therapy exists * World Health Organization (WHO) performance status 0-2 * One or more measurable lesions Exclusion Criteria: * Prostate cancer * Untreated unstable brain or meningeal metastases * Specific laboratory ranges * Pregnant or breast-feeding women * Any evidence of severe or uncontrolled diseases * Participation in other trials within 30 days
References
Publications (0)
Data not yet available
No reference posted for this study.